BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18502127)

  • 21. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
    Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors.
    Tari LW; Hoffman ID; Bensen DC; Hunter MJ; Nix J; Nelson KJ; McRee DE; Swanson RV
    Bioorg Med Chem Lett; 2007 Feb; 17(3):688-91. PubMed ID: 17157005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
    Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
    Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
    Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of potent and bioavailable GSK-3beta inhibitors.
    Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
    J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
    Shin D; Lee SC; Heo YS; Lee WY; Cho YS; Kim YE; Hyun YL; Cho JM; Lee YS; Ro S
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5686-9. PubMed ID: 17764934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors.
    Gentile G; Bernasconi G; Pozzan A; Merlo G; Marzorati P; Bamborough P; Bax B; Bridges A; Brough C; Carter P; Cutler G; Neu M; Takada M
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4823-7. PubMed ID: 21764580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
    Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
    Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3.
    Testard A; Logé C; Léger B; Robert JM; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3419-23. PubMed ID: 16644220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors.
    Gentile G; Merlo G; Pozzan A; Bernasconi G; Bax B; Bamborough P; Bridges A; Carter P; Neu M; Yao G; Brough C; Cutler G; Coffin A; Belyanskaya S
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1989-94. PubMed ID: 22310227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.